Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib plus capecitabine in chemotherapy-resistant colorectal cancer with an activated TGF-beta signature
NL-OMON46888Phase 2Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of galunisertib and capecitabine in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Primary endpoints: Recommended phase 2 dose and Response rate. Planned start Dec 2016; status: withdrawn.
02
Drugs
galunisertibcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON46888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46888.